Erschienen in:
01.09.2006 | ORIGINAL PAPER
Midbrain dopamine D2/3 receptor binding in schizophrenia
verfasst von:
Heli Tuppurainen, MD, Jyrki T. Kuikka, PhD, Mikko P. Laakso, MD, PhD, Heimo Viinamäki, MD, PhD, Minna Husso, PhL, Jari Tiihonen, MD, PhD
Erschienen in:
European Archives of Psychiatry and Clinical Neuroscience
|
Ausgabe 6/2006
Einloggen, um Zugang zu erhalten
Abstract
Several studies suggest that dysregulation of dopaminergic transmission in the midbrain and thalamus may contribute to the symptomatology of schizophrenia. The objective of this study was to examine the putative alteration of dopamine D2/3 receptor densities in the thalamus and midbrain of drug-naïve schizophrenic patients. We used the high-affinity single-photon emission tomography ligand [123I]epidepride for imaging D2/3 receptor binding sites in six neuroleptic-naïve schizophrenic patients, and seven healthy controls. Schizophrenic symptoms were evaluated by the Positive and Negative Syndrome Scale. Significantly lower D2/3 values were observed in the midbrain of patients with schizophrenia compared to controls (P = 0.02). No statistically significant difference was observed in the thalamus between two groups. Negative correlations were found between thalamic D2/3 receptor binding and general psychopathological schizophrenic symptoms (r from −0.78 to −0.92). These observations implicate altered dopaminergic activity in the midbrain of schizophrenic patients.